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Introduction
Single nucleotide polymorphisms (SNPs) are common
(1%) variations in DNA sequence, that can be the reason
for individual variability in drug efficacy and drug safety.
Objectives
To investigate the effect of single nucleotide polymorph-
isms in the genes for methotrexate (MTX) uptake and
efflux mechanisms and in the genes of the adenosine
pathway on response to therapy in JIA.
Methods
The data of 116 consecutive patients with JIA treated with
MTX at the University Children’s Hospital Ljubljana from
June 2011 to May 2014 have been retrospectively
reviewed. The disease activity was measured by JADAS 71
score 3 and 6 months after the beginning of treatment
with MTX and at the last follow up visit. All adverse
events were noted separately for different organ systems.
Genotyping of single nucleotide polymorphisms (SNP) in
the genes of MTX transporters and in the adenosine
pathway was performed using real time PCR methods.
The following SNPs were analyzed: ABCB1 3435C>T
(rs1045642),ABCC2 24C>T (rs717620), ABCC2 1019A>G
(rs2804402), ABCC2 1249G>A (rs2273697), ABCG2
34G>A (rs2231137),ABCG2 421C>A (rs 2231142),
SLCO1B1 174Ala>Val (rs4149056), SLCO1B1 388 A>G
(rs2306283), SLCO1B1 int13 T>C (rs11045879), SLC19A1
(RFC1) 80G>A (rs1051266), ATIC (347C>G), AMPD
(34C>T) and ITPA (94A>C). Kaplan Meier estimater and
penalized Cox regression model were used for statistical
analysis.
Results
The study group included 88 (76%) girls and 28 (24%)
boys with JIA. 10 (9%) patients had systemic arthritis, 43
(37%) patients had polyarthritis (5 out of these were RF
positive), 25 (22%) patients had persistent oligoarthritis, 22
(19%) extended oligoarthritis, 10 (9%) patients had juvenile
psoriatic arthritis and 2 (2%) patients suffered from enthe-
sitis related arthritis. Mean follow up time was 80 months.
75 (65%) patients were switched to higher dosage od
methotrexate to achieve inactive disease. In total 52 (45%)
patients had to be switched to biologic therapy due to
treatment inefficacy or severe adverse events. Mean treat-
ment duration until switching to biologic therapy was
17,5 months. Adverse events developed in 70 (60%)
patients, 14 (12%) patients had severe adverse events and
10 (9%) patients discontinued MTX treatment because of
adverse events. 16 (14%) patients were in remission with-
out therapy at the last follow up visit.
Using Kaplan Meier estimater ABCB1 3435C>T
(rs1045642) and ABCC2 1249G>A (rs2273697) were asso-
ciated with probability of starting biological treatment
(P=0,1 and P=0,15). Using a penalized Cox regression
model, ABCC2 1249G>A (rs2273697) was confirmed to
be found associated to probability of starting biological
treatment (HR=1.09 mutated vs wt).
Conclusion
ABCC2 1249G>A (rs2273697) could be a useful early
predictor for MTX treatment inefficacy. SNPs in MTX
transporter genes and in the adenosine pathway could be
factors to predict treatment outcome, but more studies
need to be done.
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